Quidel Corp
Slēgts
18.23
Pārskats
Akcijas cenas izmaiņa
24h
Min
17.94
Max
18.93
Ienākumi | 39M -92M |
|---|---|
Pārdošana | -104M 620M |
Peļņas marža | -14.811 |
Darbinieki | 6,500 |
Rekomendācijas | Neitrāls |
|---|---|
Prognoze 12 mēnešiem | -25.23% downside |
Nākamie ieņēmumi | 2026. g. 4. aug. |
|---|
Tirgus kapitalizācija | 340M 1B |
|---|---|
Iepriekšējā atvēršanas cena | 18.23 |
Iepriekšējā slēgšanas cena | 18.23 |
Quidel Corp Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
Quidel Corp Prognoze
Cenas mērķis
By TipRanks
-25.23% uz leju
Prognoze 12 mēnešiem
Vidējais 13.63 USD -25.23%
Augstākais 18 USD
Zemākais 12 USD
Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Quidel Corp — pēdējo 3 mēnešu laikā.
Finanšu rādītāji
Pārdošanas un administrēšanas izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
Pamatdarbības peļņa
$
Par Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
